iCAD (NASDAQ:ICAD) will release its earnings data before the market opens on Thursday, August 1st. Analysts expect iCAD to post earnings of ($0.10) per share for the quarter.
iCAD (NASDAQ:ICAD) last announced its earnings results on Tuesday, May 7th. The technology company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.08. iCAD had a negative net margin of 36.24% and a negative return on equity of 54.45%. The firm had revenue of $6.77 million for the quarter, compared to the consensus estimate of $6.10 million. On average, analysts expect iCAD to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
ICAD traded down $0.17 during trading hours on Wednesday, hitting $6.50. 516 shares of the company’s stock were exchanged, compared to its average volume of 109,497. iCAD has a 12-month low of $2.42 and a 12-month high of $7.22. The stock’s 50 day moving average price is $6.39. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.33 and a current ratio of 1.47. The stock has a market cap of $128.28 million, a price-to-earnings ratio of -17.68 and a beta of 1.05.
Separately, ValuEngine raised shares of XCel Brands from a “sell” rating to a “hold” rating in a research report on Tuesday, July 9th.
iCAD Company Profile
iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.
Further Reading: What is Compound Annual Growth Rate (CAGR)?
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.